UnitedHealth Amedisys Deal: Optimism Confirmed
- UnitedHealth Group (UNH) has reiterated its confidence in the proposed merger with Amedisys (AMED), despite ongoing antitrust concerns and a Department of Justice (DOJ) inquiry.
- The document's release followed an incident where an early draft, labeled confidential, was mistakenly sent to a STAT reporter.
- Both versions of the document address the proposed merger with Amedisys, a deal complicated by antitrust scrutiny and a DOJ investigation.
UnitedHealth Group doubles down on its Amedisys merger aspirations, despite facing persistent antitrust scrutiny and a Department of justice investigation. The company, in a document intended for shareholders, reaffirmed its commitment to the deal, emphasizing the potential benefits of improved patient outcomes and reduced costs through value-based care. While previous attempts to appease regulators through asset divestitures have failed, UnitedHealth remains optimistic.this comes as the company defends its Medicare Advantage program amid fraud allegations. News Directory 3 covers the latest developments in this high-stakes corporate saga. Discover what’s next for the UnitedHealth / Amedisys deal.
UnitedHealth Group Remains Optimistic About Amedisys Merger Amid Scrutiny
Updated june 05, 2025
UnitedHealth Group (UNH) has reiterated its confidence in the proposed merger with Amedisys (AMED), despite ongoing antitrust concerns and a Department of Justice (DOJ) inquiry. The company addressed the merger in a document initially shared with shareholders.
The document’s release followed an incident where an early draft, labeled confidential, was mistakenly sent to a STAT reporter. After STAT notified UnitedHealth of its intent to report on the document, UnitedHealth published a revised version on its website.
Both versions of the document address the proposed merger with Amedisys, a deal complicated by antitrust scrutiny and a DOJ investigation. Despite these challenges, UnitedHealth remains positive about the potential benefits of the merger, emphasizing improved patient outcomes and cost reduction through value-based care expertise.
To address antitrust concerns regarding the UnitedHealth Amedisys merger, the companies have twice attempted to divest assets. An initial plan to sell over 100 home health and hospice locations to VitalCaring was halted in January. Subsequently, a divestiture agreement with the Pennant Group (PNTG) and BrightSpring Health Services (BTSG) was reportedly rejected by the DOJ.
The shareholder document also addressed the DOJ’s “potential investigations.”
“We remain optimistic that we will complete our proposed merger with Amedisys,” the document read. “amedisys’ commitment to quality and care innovation within the home, and the patient-first culture of its people combined with optum’s deep value-based care expertise, can drive meaningful betterment in the health outcomes and experiences of more patients at lower costs, leading to continued growth for both organizations.”
UnitedHealth also responded to Wall Street Journal (WSJ) reports regarding a DOJ investigation into potential Medicare Advantage fraud.The company declined to comment on “allegations and speculation,” but defended its Medicare Advantage program.
“If pushed on WSJ stories: The Wall street Journal used flawed analysis and inaccurate data to paint an incomplete picture of a program that provides better health outcomes and more affordable health care for millions of seniors,” the leaked document read.
The company asserted its strong support for the integrity of its Medicare Advantage program and advocated for more frequent audits by the Centers for Medicare & Medicaid Services (CMS).
What’s next
The future of the UnitedHealth and Amedisys merger hinges on the resolution of antitrust concerns and the DOJ investigation.Further divestiture attempts or legal challenges could significantly impact the deal’s outcome.